Cefepime/Zidebactam(Cefepime/Zidebactam) - 药物靶点：PBP3_在研适应症：急性肾盂肾炎，复杂的尿路感染，细菌感染_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Zidebactam/cefepime intravenous

靶点

PBP3

作用机制

PBP3抑制剂(细菌青霉素结合蛋白3抑制剂)、细胞壁抑制剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

University of East Anglia

ACS Dobfar SpA

+ [1]

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

结构

分子式C13H21N5O7S

InChIKeyYCZPXRQPDCXTIO-BBBLOLIVSA-N

CAS号1436861-97-0

查看全部结构式(2)

关联

7

项与 Cefepime/Zidebactam 相关的临床试验

CTR20222627 / Recruiting临床3期

一项在复杂性尿路感染或急性肾盂肾炎成人受试者治疗中确定头孢吡肟-zidebactam与美罗培南的有效性和安全性的随机、双盲、多中心的3期对比研究

主要目的：证明头孢吡肟-zidebactam（FEP-ZID）在以下方面非劣效于美罗培南：检查治愈情况（TOC）访视时微生物学改良的意向治疗（mMITT）人群中的总体成功率（临床治愈+微生物根除率）; 评估FEP-ZID在安全性人群中的总体安全性和耐受性; 次要目的：评价TOC时临床可评价（CE）和微生物学可评价（ME）人群中的总体疗效; 评价治疗结束（EOT）时mMITT人群中的总体疗效; 评价EOT（mMITT人群）和TOC（mMITT、CE和ME人群）时的临床结果; 评价EOT（mMITT人群）和TOC（mMITT、CE和ME人群）时的微生物学结果; 评价TOC时按致病菌划分的总体疗效（mMITT、CE和ME人群）以及按致病菌划分的临床结果（mMITT和CE人群）和微生物学结果（mMITT和ME人群）; 评价后期随访（LFU）时mMITT人群的临床结果; 评价FEP-ZID用于治疗复杂性尿路感染（cUTI）或急性肾盂肾炎（AP）成人受试者时的药代动力学（PK）;

开始日期2024-05-25

申办/合作机构

Wockhardt Bio AG

[+2]

CTR20233796 / Completed临床1期

一项在中国健康受试者中评价FEP-ZID的药代动力学、安全性和耐受性的随机、双盲、安慰剂对照、单次给药I期研究

本研究的主要目的是：在中国健康受试者中评价3 g头孢吡肟-zidebactam（FEP-ZID）单次静脉注射（IV）给药的药代动力学（PK）。本研究的次要目的是：在中国健康受试者中评价3 g FEP-ZID单次IV给药的安全性和耐受性。

开始日期2024-05-10

申办/合作机构

Wockhardt Bio AG

[+2]

NCT04979806 / Recruiting临床3期

A Phase 3, Randomized, Double-blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-zidebactam vs. Meropenem in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis in Adults

This is a Phase 3, randomized, double-blind, multicenter, non-inferiority study to evaluate the efficacy, safety, and tolerability of FEP-ZID vs. meropenem in the treatment of hospitalized adults with cUTI or AP.
Approximately 528 hospitalized adult subjects (≥ 18 years of age) diagnosed with cUTI or AP will be enrolled in the study. The diagnosis of cUTI or AP will be based on a combination of clinical symptoms and signs plus the presence of pyuria. The total duration of treatment with study drug is 7 to 10 days. Each subject must remain hospitalized during the study drug treatment period; no outpatient parenteral antibiotic therapy is allowed.

开始日期2022-08-28

申办/合作机构

Wockhardt Ltd.

[+1]

100 项与 Cefepime/Zidebactam 相关的临床结果

登录后查看更多信息

100 项与 Cefepime/Zidebactam 相关的转化医学

登录后查看更多信息

100 项与 Cefepime/Zidebactam 相关的专利（医药）

登录后查看更多信息

17

项与 Cefepime/Zidebactam 相关的文献（医药）

2022-06-29·Journal of Antimicrobial Chemotherapy2区 · 医学

Inoculum effects of cefepime/zidebactam (WCK 5222) and ertapenem/zidebactam (WCK 6777) for Enterobacterales in relation to β-lactamase type and enhancer effect, as tested by BSAC agar dilution

2区 · 医学

Article

作者: Vickers, Anna ; Mushtaq, Shazad ; Woodford, Neil ; Livermore, David M ; Chaudhry, Aiysha

AbstractObjectivesCombinations of PBP3-active β-lactams with developmental diazabicyclooctanes (DBOs), e.g. zidebactam, remain active against many MBL producers via an enhancer effect. We explored how this activity is affected by inoculum.Materials and methodsMICs of zidebactam and its cefepime and ertapenem combinations (WCK 5222 and WCK 6777, respectively) were determined by BSAC agar dilution at inocula from 3–6 × 103 to 3–6 × 105 cfu/spot. Isolates, principally Klebsiella spp., were chosen as having previously tested resistant to zidebactam or its cefepime combination, and by β-lactamase type.ResultsMICs of zidebactam, tested alone, were strongly inoculum dependent regardless of β-lactamase type; MICs of its cefepime and ertapenem combinations likewise were strongly inoculum dependent—rising ≥32-fold across the inoculum range tested—but only for MBL producers. Combination MICs for isolates with non-MBLs, including those with OXA-48 (where the enhancer effect remains critical for ertapenem/zidebactam) were much less inoculum dependent, particularly for cefepime/zidebactam. MBL producers frequently moved between putative ‘susceptible’ (MIC ≤ 8 + 8 mg/L) and ‘resistant’ (MIC > 8 + 8 mg/L) categories according to whether the inoculum was at the high or low end of BSAC’s acceptable (1–4 × 104 cfu/spot) range.ConclusionsThe activity of zidebactam combinations against MBL producers, which strongly depends on the enhancer effect, is inoculum dependent. Animal data suggest consistent in vivo activity even in high-inoculum pneumonia models. Contingent on this being supported by clinical experience, the combination behaviour may be best represented by the MICs obtained at the lower end of BSAC’s inoculum range.

2022-02-23·Microbiology Spectrum2区 · 生物学

Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate

2区 · 生物学

Article

作者: Jin, Yongxin ; Wu, Weihui ; Liang, Qi’an ; Ren, Huan ; Song, Yuqin ; Cheng, Zhihui ; Zhao, Xinrui ; Tian, Zhenyang ; Bai, Fang ; Feng, Jie ; Pan, Xiaolei

Antibiotic resistance imposes a severe threat on human health. WCK 5222 is a β-lactam/β-lactamase inhibitor combination that is composed of cefepime and zidebactam.

2021-08-12·Journal of Antimicrobial Chemotherapy2区 · 医学

Comparative in vivo activity of human-simulated plasma and epithelial lining fluid exposures of WCK 5222 (cefepime/zidebactam) against KPC- and OXA-48-like-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model

2区 · 医学

Article

作者: Lasko, Maxwell J. ; Abdelraouf, Kamilia ; Nicolau, David P.

AbstractObjectivesThis was a comparative assessment of WCK 5222 (cefepime/zidebactam 2/1 g as a 1 h infusion every 8 h) efficacy using human-simulated plasma and ELF exposures against serine-carbapenemase-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model.MethodsTen clinical isolates were utilized: eight were serine-carbapenemase-producing (KPC, n = 4; OXA-48-like, n = 4) Enterobacterales with WCK 5222 MICs (1:1) ranging from 1 to 4 mg/L; and two were previously studied MDR isolates serving as quality controls. Lungs of mice were inoculated with 50 μL of 107 cfu/mL. Treatment mice received human-simulated regimens of cefepime, zidebactam or WCK 5222 derived from plasma or epithelial lining fluid (ELF) profiles obtained from healthy subjects. Lung bacterial densities resulting from the humanized exposures in plasma and ELF were compared.ResultsInitial lung bacterial densities ranged from 6.06 to 6.87 log10 cfu/lungs, with a mean bacterial burden increase to 9.06 ± 0.42 after 24 h. Human-simulated plasma and ELF exposures of cefepime and zidebactam monotherapy had no activity. Human-simulated WCK 5222 plasma exposures resulted in a >1 log10 cfu/lungs reduction in bacterial burden for all isolates. Humanized WCK 5222 ELF exposures achieved a >1 log10 cfu/lungs reduction for all isolates. While statistically significant differences in bacterial burden reduction were observed between the plasma and ELF exposures for WCK 5222 in 5/8 isolates, all treatments achieved the translational kill target of a >1 log10 cfu reduction.ConclusionsClinically achievable WCK 5222 plasma and ELF exposures produced in vivo killing of carbapenem-resistant Enterobacterales in the neutropenic murine pneumonia model that is predictive of efficacy in humans.

100 项与 Cefepime/Zidebactam 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性肾盂肾炎	临床3期	保加利亚	Wockhardt Ltd.	2022-08-28
急性肾盂肾炎	临床3期	秘鲁	Wockhardt Ltd.	2022-08-28
急性肾盂肾炎	临床3期	印度	Wockhardt Ltd.	2022-08-28
急性肾盂肾炎	临床3期	中国	Wockhardt Ltd.	2022-08-28
急性肾盂肾炎	临床3期	墨西哥	Wockhardt Ltd.	2022-08-28
急性肾盂肾炎	临床3期	爱沙尼亚	Wockhardt Ltd.	2022-08-28
急性肾盂肾炎	临床3期	波兰	Wockhardt Ltd.	2022-08-28
急性肾盂肾炎	临床3期	美国	Wockhardt Ltd.	2022-08-28
急性肾盂肾炎	临床3期	立陶宛	Wockhardt Ltd.	2022-08-28
复杂的尿路感染	临床3期	立陶宛	Wockhardt Ltd.	2022-08-28